Black flag protests in Tamil Nadu against PM's Madurai visit

New Delhi, Jul 3: In a significant step, ICMR has partnered with Bharat Biotech International Limited (BBIL) to fast-track clinical trials of the indigenous COVID-19 vaccine (BBV152 COVID Vaccine). It is the first indigenous vaccine being developed by India and is one of the top priority projects which is being monitored at the topmost level of the Government, says ICMR in a statement.

The vaccine is derived from a strain of SARS-CoV-z isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine.

In a letter to the institutes that will be involved in the trails of the vaccine, ICMR has said

"It is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials. BBIL is working expeditiously to meet the target. However, final outcome will depend on the cooperation of all clinical trial sites involved in this project. you have been chosen as a clinical trial site of the BBV152 COVID vaccine. ln view of the public health emergency due to COVID-19 pandemic and urgency to launch the vaccine, you are strictly advised to fast track all approvals related to initiation of the clinical trial and ensure that the subject enrollment is initiated no later than 7th July 2020."

The ICMR also asked the institutes to comply with the order, "Kindly note that non-compliance will be viewed very seriously. Therefore, you are advised to treat this project on the highest priority and meet the given timelines without any lapse."

The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of the country's first indigenous COVID-19 vaccine.

New Delhi, April 6: On the 40th foundation day of the Bharatiya Janata Party (BJP) today, Prime Minister Narendra Modi appealed to party workers to reaffirm the importance of social distancing, help those in need amid lockdown and enable India to overcome COVID-19.

"Greetings to all fellow BJP Karyakartas on the Sthapana Diwas of the party. Tributes to all those who have toiled hard to build the party for decades, due to which BJP has got the opportunity to serve crores of Indians across our nation's length and breadth. #BJPat40," Prime Minister Modi tweeted.

"Whenever BJP has got the opportunity to serve, the party has focused on good governance and empowering the poor. In line with the party's ethos, our Karyakartas have worked hard to bring a positive difference in the lives of many and done great social service.

We mark our party's 40th anniversary when India is battling COVID-19. I appeal to BJP Karyakartas to follow the set of guidelines from our party president JP Nadda Ji, help those in need and reaffirm the importance of social distancing. Let's make India COVID-19 free," he added.

Earlier, in a message, party President JP Nadda had asked BJP workers to hoist new party flag at all offices and at every karyakarta's house. "Maintain social distancing while hoisting," the BJP President stated.

"All BJP Karyakartas to give up one meal on our Foundation Day as a way to show solidarity with people facing hardships during the lockdown.

Provide food packets to 5+1 needy under #FeedtheNeedy program. In the next one week, put a system in place where we can provide two homemade face covers to each person at our booth. We should circulate videos of preparation and distribution of such face covers with #WearFaceCoverStaySafe," Nadda stated.

He also asked BJP Kartyakartas to encourage 40 others to donate Rs 100 each to PM-CARES Fund.

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.